- Home
- BYSI
BYSI
BeyondSpring Inc.
as 11-11-2025 3:54pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Upcoming Earnings Alert:
Get ready for potential market movements as BeyondSpring Inc. BYSI prepares to release earnings report on 13 Nov 2025.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 79.0M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 47.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $3.44 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of BeyondSpring Inc. (BYSI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 17 '25 | Sell | $1.76 | 45,513 | $80,102.88 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 16 '25 | Sell | $1.72 | 85,798 | $147,572.56 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 15 '25 | Sell | $1.65 | 17,960 | $29,634.00 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 14 '25 | Sell | $1.65 | 28,495 | $47,016.75 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 13 '25 | Sell | $1.70 | 107,361 | $182,513.70 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 10 '25 | Sell | $1.77 | 2,390 | $4,230.30 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 9 '25 | Sell | $1.81 | 3,979 | $7,201.99 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 8 '25 | Sell | $1.77 | 7,507 | $13,287.39 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 7 '25 | Sell | $1.79 | 2,100 | $3,759.00 | 1,518,893 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Oct 6 '25 | Sell | $1.78 | 17,500 | $31,150.00 | 1,518,893 |
Latest BeyondSpring Inc. News
BYSI Breaking Stock News: Dive into BYSI Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
GlobeNewswire
5 months ago
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire
5 months ago
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Simply Wall St.
6 months ago
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
GlobeNewswire
6 months ago
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
8 months ago
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire
8 months ago
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
GlobeNewswire
9 months ago
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Compare BYSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.